메뉴 건너뛰기




Volumn 20, Issue SUPPL. 1, 2001, Pages

Current and future treatment of hepatitis C

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; CONSENSUS INTERFERON; INTERFERON; INTERLEUKIN 10; MYCOPHENOLIC ACID; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE; PEGYLATED INTERFERON ALPHA2A; RIBAVIRIN; RIBOZYME; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS RNA;

EID: 0035082609     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (25)

References (26)
  • 2
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon-alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    • International Hepatitis Interventional Therapy Group (IHIT)
    • (1998) Lancet , vol.352 , Issue.9138 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3    Niederau, C.4    Minuk, G.S.5    Ideo, G.6
  • 14
    • 0033547723 scopus 로고    scopus 로고
    • Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: What is the status today?
    • (1999) Schweiz Med Wochenschr , vol.129 , pp. 8-10
    • Renner, E.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.